Coenzyme Q10: Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).
Placebo: The placebo was administered from hospital admission until one month after discharge.
Study summary
This study aimed to assess the effectiveness of Coenzyme Q10 in preventing both acute and chronic pain following thoracoscopic surgery, with a focus on its potential benefits in reducing the incidence and severity of pain.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 18-75 years;
* American Society of Anesthesiology (ASA) physical status classification I-III;
* Scheduled for elective lung resection surgery under thoracoscopy;
* Voluntarily opting for patient-controlled intravenous analgesia;
* Willing to participate in this trial after consultation with the patient or their family and signing the informed consent form.
Exclusion Criteria:
* History of previous thoracotomy or thoracoscopic surgery;
* Patients converted to open thoracotomy intraoperatively;
* Severe hepatic or renal dysfunction;
* History of substance abuse;
* Pregnancy or breastfeeding;
* History of chronic pain;
* Use of coenzyme Q10 for more than one month;
* Allergy to coenzyme Q10;
* Patients unable to communicate or cooperate.
Primary outcome measure(s)
The incidence of chronic postsurgical pain — from the end of surgery to 3 months after surgery
Trial sites (1)
Facility
City
Region
Status
Guangyou Duan
Chongqing
Chongqing Municipality
Recruiting
More The Second Affiliated Hospital of Chongqing Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.